Assembly Biosciences
11711 North Meridian Street
Suite 310
Indianapolis
Indiana
46032
United States
Tel: 855.971.4467
Website: http://www.assemblybio.com/
Email: info@assemblybio.com
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.
Stock Exchange: NASDAQ
Stock Symbol: ASMB
R & D Main Facility:
Assembly Biosciences
331 Oyster Point Blvd.
South San Francisco, CA 94080
132 articles about Assembly Biosciences
-
Assembly Biosciences To Present Data At The International Liver Congress 2016 That Supports Advancing Its CpAM Candidates Into HBV Clinical Trials
4/13/2016
-
Assembly Biosciences To Present Data On New Series Of HBV Core Protein Allosteric Modifiers At The International Liver Congress™ 2016
3/30/2016
-
Assembly Biosciences Expands Senior Leadership Team
1/11/2016
-
Assembly Biosciences Appoints Biotech Veteran Alan J. Lewis To Board Of Directors
12/21/2015
-
Assembly Biosciences To Present At Jefferies Microbiome Summit
12/16/2015
-
Clinical Study Shows Assembly Biosciences' Oral Gemicel Technology Can Achieve Targeted Delivery To The Lower GI Tract For Microbiome And Other Applications
12/9/2015
-
Assembly Biosciences To Describe Improved Methods For HBV Drug Development At Major International Meeting
10/6/2015
-
Assembly Biosciences Discusses Mechanism Of Action Of Its HBV Antiviral Program At 2nd ANRS HBV Cure Workshop
5/19/2015
-
Assembly Biosciences Announces Proposed Public Offering Of Common Stock
3/19/2015
-
Ventrus Biosciences, Inc. Becomes Assembly Biosciences As Stockholders Approve Merger With Assembly Pharmaceuticals
7/14/2014
-
Ventrus Biosciences, Inc. To Merge With Assembly Pharmaceuticals
5/19/2014
-
Assembly Pharmaceuticals And BioCrossroads Announce Investment To Advance Potentially Curative Therapy For Chronic Hepatitis B Virus
4/11/2014